SAN DIEGO, Jan. 11, 2017
SAN DIEGO, Jan. 11, 2017 /PRNewswire/ -- Shareholder rights law firm Johnson & Weaver, LLP has launched an investigation into whether the board members of Derma Sciences, Inc. (NASDAQ: DSCI) breached their fiduciary duties in connection with the proposed sale of the Company to Integra LifeSciences Holdings Corporation. Derma operates as a medical device company in the wound care market.
On January 10, 2017, Derma announced it had signed a definitive merger agreement with Integra. Under terms of the agreement, Integra will acquire all of the outstanding shares of Derma for $7 per share.
The investigation concerns whether the Derma board failed to satisfy their duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Derma shares of common stock. Nationally recognized Johnson & Weaver is investigating whether the proposed deal price represents adequate consideration, especially given one Wall Street analyst has a $8.50 price target on the stock.
If you are a shareholder of Derma and believe the proposed buyout price is too low and you're interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker (firstname.lastname@example.org) at 619-814-4471.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/derma-dsci-alert-johnson--weaver-llp-launches-an-investigation-into-the-fairness-of-price-and-process-in-proposed-sale-of-derma-sciences-inc-is-7-a-fair-price-300389351.html
SOURCE Johnson & Weaver, LLP